scholarly journals A Study of Some of the World’s Most Innovative Universities

2021 ◽  
pp. 25-81
Author(s):  
Abdulrahman Obaid Al-Youbi ◽  
Adnan Hamza Mohammad Zahed ◽  
Mahmoud Nadim Nahas ◽  
Ahmad Abousree Hegazy
Keyword(s):  
Link Type ◽  
The World

AbstractThis chapter examines in detail a study of the top twenty most innovative universities in the world according to Table 10.1007/978-3-030-59694-1_6. A study of one university of each country, whose name was not included among the top twenty universities, is also added. The first-ranked university in each country which none of its universities were ranked among the top twenty is selected, and its details described the same way as that of the top twenty universities. The ranking of the added universities is: 31, 35, 44, 55, 57, 62, and 63. This study is shown below.

scholarly journals 417 Phase 3 study of pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib as first-line treatment for advanced renal cell carcinoma

2021 ◽  
Vol 9 (Suppl 3) ◽  
pp. A447-A447
Author(s):  
Toni Choueiri ◽  
Elizabeth Plimack ◽  
Thomas Powles ◽  
Martin Voss ◽  
Howard Gurney ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Antitumor Activity ◽  
Line Treatment ◽  
First Line ◽  
Phase 3 ◽  
End Points ◽  
Once Daily ◽  
Link Type ◽  
The World ◽  
First Line Treatment

BackgroundPembrolizumab + vascular endothelial growth factor (VEGF) inhibitor lenvatinib demonstrated antitumor activity as first-line treatment for advanced clear cell renal cell carcinoma (ccRCC) in phase 3 trial KEYNOTE-581/CLEAR (NCT02811861). Hypoxia-inducible factor 2α (HIF-2α) inhibitor belzutifan (MK-6482) showed antitumor activity in ccRCC, and a coformulation of pembrolizumab and CTLA-4 inhibitor quavonlimab (MK-1308A) showed antitumor activity in non–small cell lung cancer. HIF-2α or CTLA-4 inhibition with PD-1 and VEGF inhibition backbone combination may provide additional benefit as first-line treatment in ccRCC. This open-label, randomized, phase 3 study (NCT04736706) will be conducted to compare novel combination therapies pembrolizumab + belzutifan + lenvatinib (arm A) and MK-1308A + lenvatinib (arm B) with pembrolizumab + lenvatinib (arm C).MethodsApproximately 1431 adults with metastatic ccRCC, measurable disease per RECIST v1.1, and Karnofsky Performance Status Scale score ≥70% who had not previously undergone systemic therapy for advanced ccRCC will be enrolled. Patients will be randomly assigned 1:1:1 to arm A (belzutifan 120 mg + lenvatinib 20 mg oral once daily + pembrolizumab 400 mg IV every 6 weeks), arm B (MK-1308A [quavonlimab 25 mg + pembrolizumab 400 mg] IV every 6 weeks and lenvatinib 20 mg oral once daily), or arm C (pembrolizumab 400 mg IV every 6 weeks + lenvatinib 20 mg oral once daily). Treatment will continue until documented disease progression, withdrawal of consent, or other discontinuation event; patients will receive pembrolizumab and MK-1308A for up to 18 cycles (approximately 2 years). Patients will be stratified by International mRCC Database Consortium (IMDC) score (favorable vs intermediate vs poor), region of the world (North America vs Western Europe vs rest of the world), and sarcomatoid features (yes vs no). Response will be assessed by CT or MRI per RECIST v1.1 by blinded independent central review (BICR) at week 12 from randomization, every 6 weeks through week 78, and every 12 weeks thereafter. Adverse events and serious adverse events will be monitored throughout the study and for 90 days after treatment. Dual primary end points are progression-free survival per RECIST v1.1 by BICR and overall survival. Primary end points will be assessed in arm A compared with arm C and in arm B compared with arm C for patients with IMDC intermediate/poor status and in all patients regardless of IMDC status. Secondary end points are objective response rate and duration of response per RECIST v1.1 by BICR, patient-reported outcomes, and safety.AcknowledgementsMedical writing and/or editorial assistance was provided by Matthew Grzywacz, PhD, of ApotheCom (Yardley, PA, USA). This assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and Eisai Inc., Woodcliff Lake, NJ, USA. Funding for this research was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA,Eisai Inc., Woodcliff Lake, NJ, USA.Trial RegistrationClinicaltrials.gov, NCT04736706Ethics ApprovalThe study and the protocol were approved by the Institutional Review Board or ethics committee at each site.

scholarly journals A SYSTEMATIC ANALYSIS OF THE TIME COURSE TO DEVELOP TREATMENTS FOR COVID-19

2020 ◽  
Author(s):  
Binh T. Ngo ◽  
Marc S. Rendell
Keyword(s):  
Clinical Trials ◽  
Time Course ◽  
The United States ◽  
Hospitalized Patients ◽  
World Health ◽  
Published Data ◽  
Link Type ◽  
Vaccine Trials ◽  
The World ◽  
Google Search

ABSTRACTBackgroundThe spread of COVID-19 from Wuhan in China throughout the world has been alarmingly rapid. Epidemiologic techniques succeeded in containing the disease in China, but efforts were not as successful in the rest of the world, particularly the United States where there have been 2,079,592 confirmed cases with 115,484 deaths as of June 15, 2020. Projections are for continued new infections and deaths if no effective treatments can be activated over the next six months. We performed a systematic review to determine the potential time course for development of treatments and vaccines focusing on availability in the last half of 2020.MethodsPublicationsOur search was performed during the week of June 15, 2020 We reviewed up to date information from several sources to identify potential treatments for COVID-19: We used the Reagan-Udall Expanded Access Navigator COVID-19 Treatment Hub to track the efforts of companies to develop treatments. We then used the results to search for publications identified treatments on pubmed.gov and on medRxiv, the preprint server. We further used a targeted Google search to find announcements of trial results.Clinical TrialsWe searched for all investigational trials begun in the first quarter of 2020, with cut off on April 1, using several different sources: (A) covid-trials.org, then validated results on (B) clinicaltrials.gov and the (C) World Health Organization’s International Clinical Trials Registry Platform (WHO ICTRP). We focused on trials which were completed or currently recruiting for patients, reasoning that the timeline to arrive at treatments by the end of the year would require completion within the next 6 months. We excluded studies which were clearly observational, with no randomization, control or comparison group. We further set a cutoff of 100 for numbers of subjects since smaller trial size could lack statistical power to establish superiority of the intervention over the control condition.ResultsPublished DataWe found 43 publications reporting findings on 1 classes of agents. There were 12 publications related to hydroxychloroquine (HCQ),11 on tocilizumab, 4 publications related to remdesivir, four on lopanovir/ritonavir (LPV/R), four on interferons, two on favipiravir, two on convalescent plasma, one on meplazumab, one on corticosteroids, one on famotidine, and one on ivermectin. Of these, only 16 were randomized or active control studies; the rest were retrospective observational. Only two publications dealt with outpatient care, the rest all in hospitalized patients.Clinical TrialsWe found 409 trials meeting our minimum requirement of 100 subjects which were recruiting or completed. The WHO has launched the Solidarity megatrial performed in over 100 countries actively comparing HCQ, lopanovir/ritonavir (LPV/R) alone and in combination with interferon beta-1, and remdesivir. That trial is scheduled to complete enrollment in the first quarter of 2021. In addition, we found 46 trials of HCQ, 11 trials of LPV/R and 8 trials of interferons. There were 18 ongoing trials of antiviral agents, 24 immune modulator trials, 9 vaccine trials, and 62 trials of other agents. We excluded a large number of trials of Chinese traditional medications, reasoning that there was insufficient clinical experience with these agents outside China to offer these treatments to the rest of the world. Forty four trials were hoping to complete enrollment by the end of the second quarter of 2020. Of these, only 9 were conducted on outpatients. A few vaccine trials are hoping to complete Phase 3 enrollment by the end of the third quarter, but a prolonged follow-up of patients will likely be required.ConclusionRemdesivir and tocilizumab have now been granted emergency authorization in many countries for treatment of hospitalized patients. However, the disease is propagated primarily by infected ambulatory individuals. There are only a few randomized controlled studies in outpatients which can be expected to yield results in time to impact on the continuing spread of the epidemic in 2020. It will be necessary for public health authorities to make hard decisions with limited data. The choices will be hardest in dealing with potential early release of vaccines.

scholarly journals A Study on the Impact and Potential of Cryptocurrency

2021 ◽  
Author(s):  
Aviral Srivastava
Keyword(s):  
Carbon Dioxide Emissions ◽  
Electronic Waste ◽  
Supply And Demand ◽  
World Market ◽  
Analysis Model ◽  
Virtual Currency ◽  
Advantages And Disadvantages ◽  
Link Type ◽  
The World ◽  
The Impact

Introduction: Cryptocurrency is an innovative decentralized virtual currency concept. It has emerged as a new type of investment vehicle in the world, much like gold. The current research was carried out to investigate the impact of cryptocurrency on the world market and its future potential in relation to its rising prominence among investors and traders alike. Methods: This descriptive-analytical study was based on the interviews of individuals trading in cryptocurrencies and data collected from magazines, websites, electronic newspapers, and research articles. The collected data sets were analyzed by a data analysis model created by me. Results: Only Cryptocurrencies with decentralized systems are trusted by investors for the fact that they can't be controlled by a single entity. Some countries have legalized crypto while some have banned them. Overall, a majority of the world still has yet to comment on the legality of Bitcoin. The cryptocurrency market is highly volatile as it is based on a simple supply and demand strategy. Bitcoin mining generates 35.95 million tons of carbon dioxide emissions and 12,000 tons of electronic waste a year. The applications of this system promise free, fast transactions, a guarantee of privacy, and a traceable supply-chain framework. Conclusion: The findings indicated that cryptocurrency has a swiftly rising user base. With its fair share of advantages and disadvantages, it is a global phenomenon. Given the correlation between investors and asset flow, its future looks promising. It is necessary to promote this next chapter in the evolution of digital assets.

News from the Net: The World of Math Online

2002 ◽  
Vol 8 (9) ◽  
pp. 531
Author(s):  
Kim Lowry
Keyword(s):  
Elementary School ◽  
Elementary School Students ◽  
Three Dimensional ◽  
Rich Source ◽  
Free Software ◽  
School Students ◽  
Link Type ◽  
Software Packages ◽  
The World

Asite called math.com (access it at www.math.com), run by Encore Software of Gardena, California, is a rich source for elementary school students and their parents and teachers. The site offers several free software packages, of which Math Express! is one. This set of three CD-ROMs contains 2600 problems in basic mathematics and beyond, with step-by-step instruction, custom quizzes, self-paced study, and three-dimensional games and puzzles.

scholarly journals canvasXpress: A versatile interactive high-resolution scientific multi-panel visualization toolkit

2017 ◽  
Author(s):  
Baohong Zhang ◽  
Shanrong Zhao ◽  
Isaac Neuhaus
Keyword(s):  
Big Data ◽  
High Resolution ◽  
Clinical Use ◽  
Scientific Communities ◽  
The Core ◽  
Link Type ◽  
The World ◽  
Cancer Mutations ◽  
Visualization Toolkit ◽  
Pdf Format

To the Editor: CanvasXpress (https://canvasxpress.org) was developed as the core visualization component for bioinformatics and systems biology analysis at Bristol-Myers Squibb and further enhanced by scientists around the world and served as a key visualization engine for many popular bioinformatics tools1,2,3,4,5,6. It offers a rich set of interactive plots to display scientific and genomics data, such as oncoprint of cancer mutations, heatmap, 3D scatter, violin, radar, and profile plots (Figure 1, canvasXpress plots arranged by canvasDesigner https://baohongz.github.io/canvasDesigner). Recently, the reproducibility and usability of the package in real world bioinformatics and clinical use cases have been improved significantly witnessed by continuous add-on features and wide adoption of the toolkit in the scientific communities. Furthermore, It is the first noteworthy package harmonizing real time interactive exploring and analyzing of big data, full-fledged customizing of look-n-feel, and producing multi-panel publication-ready figures in PDF format simultaneously.

Margareta Niculescu – A Portrait throughout a Century

2018 ◽  
Vol 8 (2) ◽  
pp. 219-231
Author(s):  
Anca Doina Ciobotaru
Keyword(s):  
Link Type ◽  
The World ◽  
Puppet Theatre ◽  
As If ◽  
What Matters

Abstract In the last century, Romanian puppet theatre has not only received, but it has also given to the world – which I would personally correct. Perhaps: “it has given to the world innovative, poetic performances that have brought about a new aesthetic vibe.” If you skim through World Encyclopaedia of Puppetry Arts (first edition published in French, under the title Encyclopédie mondiale des arts de la marionette, and second edition published in English, under the aforementioned titled, available online at: https://wepa.unima.org/en/), you will find more information on Romanian puppet theatre than you might expect. A complicated history that has been reshaped subjectively – as is the case with every history. And, given that Margareta Niculescu left this world on the 19th of August, 2018, I’ve decided to turn back to the pages 493 and 494 (from the first edition), as if going in a pilgrimage. For quite some time, I’ve been thinking of getting closer to her, all prejudices, myths and subjectivity aside; perhaps Matei Brunul 1 has also helped; do shadows make way for themselves/do they follow us? In any domain, at any time, in any place. What matters is that you want to go back into the light, to free yourself, to be able to remember.

Early Childhood Corner: Standards for Preschoolers

2000 ◽  
Vol 7 (1) ◽  
pp. 38-41
Author(s):  
Douglas Clements ◽  
Julie Sarama
Keyword(s):  
Early Childhood ◽  
School Mathematics ◽  
Link Type ◽  
The World ◽  
Principles And Standards

What position does Principles and Standards for School Mathematics (NCTM 2000) take on appropriate standards, goals, and activities for preschoolers? This article is a sample of the information from chapter 4, “Standards for Grades Pre-K–2,” which has been selected and annotated by the editors. Please read the chapter for the full story. You can find it on the World Web Web at standards.nctm.org.

scholarly journals Globetrotting strangles: the unbridled national and international transmission of Streptococcus equi between horses

2021 ◽  
Author(s):  
Catriona Mitchell ◽  
Karen F. Steward ◽  
Amelia R. L. Charbonneau ◽  
Saoirse Walsh ◽  
Hayley Wilson ◽  
...  
Keyword(s):  
Type Species ◽  
Genetic Relationships ◽  
Genomic Analysis ◽  
Economic Cost ◽  
Close Relative ◽  
International Transmission ◽  
Content Type ◽  
Link Type ◽  
Streptococcus Equi ◽  
The World

The equine disease strangles, which is characterized by the formation of abscesses in the lymph nodes of the head and neck, is one of the most frequently diagnosed infectious diseases of horses around the world. The causal agent, Streptococcus equi subspecies equi , establishes a persistent infection in approximately 10 % of animals that recover from the acute disease. Such ‘carrier’ animals appear healthy and are rarely identified during routine veterinary examinations pre-purchase or transit, but can transmit S. equi to naïve animals initiating new episodes of disease. Here, we report the analysis and visualization of phylogenomic and epidemiological data for 670 isolates of S. equi recovered from 19 different countries using a new core-genome multilocus sequence typing (cgMLST) web bioresource. Genetic relationships among all 670 S. equi isolates were determined at high resolution, revealing national and international transmission events that drive this endemic disease in horse populations throughout the world. Our data argue for the recognition of the international importance of strangles by the Office International des Épizooties to highlight the health, welfare and economic cost of this disease. The Pathogenwatch cgMLST web bioresource described herein is available for tailored genomic analysis of populations of S. equi and its close relative S. equi subspecies zooepidemicus that are recovered from horses and other animals, including humans, throughout the world. This article contains data hosted by Microreact.

scholarly journals ‘Community evolution’ – laboratory strains and pedigrees in the age of genomics

Microbiology ◽  
2020 ◽  
Vol 166 (3) ◽  
pp. 233-238
Author(s):  
Matthew J. Dorman ◽  
Nicholas R. Thomson
Keyword(s):  
Type Species ◽  
Research Groups ◽  
Content Type ◽  
Link Type ◽  
Community Evolution ◽  
The World ◽  
Evolution Experiment ◽  
Reference Strains ◽  
Generation Sequencing ◽  
Classical Genetics

Molecular microbiologists depend heavily on laboratory strains of bacteria, which are ubiquitous across the community of research groups working on a common organism. However, this presumes that strains present in different laboratories are in fact identical. Work on a culture of Vibrio cholerae preserved from 1916 provoked us to consider recent studies, which have used both classical genetics and next-generation sequencing to study the heterogeneity of laboratory strains. Here, we review and discuss mutations and phenotypic variation in supposedlyisogenic reference strains of V. cholerae and Escherichia coli , and we propose that by virtue of the dissemination of laboratory strains across the world, a large ‘community evolution’ experiment is currently ongoing.

A Brief Overview of the WPATH Companion Document on Voice and Communication

2015 ◽  
Vol 25 (2) ◽  
pp. 66-74 ◽  
Author(s):  
Shelagh Davies
Keyword(s):  
Clinical Practice ◽  
Professional Association ◽  
Evidence Based ◽  
Speech Language Pathology ◽  
Standing Committee ◽  
Transgender Health ◽  
Link Type ◽  
The World ◽  
Language Pathology ◽  
The Voice

Transgender voice and communication is an emerging area of practice within the scope of speech-language pathology. The evidence that informs this practice is still sparse, but is rapidly expanding. To support clinicians, the Voice and Communication Standing Committee of the World Professional Association for Transgender Health (WPATH) has recently prepared a document that summarizes the evidence-based literature up to 2013 and offers suggestions to guide clinical practice. This paper is a brief outline of that document, which will be available in an upcoming issue of the International Journal of Transgenderism and also, free of charge, on the WPATH website at http://www.wpath.org .

Sign in / Sign up

Export Citation Format

Share Document